Sanofi Pasteur: The Dengue Vaccine Dilemma



Sanofi Pasteur: The Dengue Vaccine Dilemma



Definition

Thecasesolutions.com

 Dengue (pronounced DENgee) fever is a painful, debilitating mosquito-borne disease caused by any one of four closely related dengue viruses. These viruses are related to the viruses that cause West Nile infection and yellow fever.

Application in medicine Thecasesolutions.com

Vaccine efficacy against confirmed dengue pooled across both trials was 59.2% in the year following the primary series (per protocol analysis). During this initial time period, pooled vaccine efficacy against severe dengue was 79.1%. Efficacy varied by serotype: vaccine efficacy was higher against serotypes 3 and 4 than for serotypes 1 and 2. Vaccine efficacy also varied by age at vaccination and serostatus at baseline (i.e., previous exposure to dengue prior to vaccination).

Pros and cons

Thecasesolutions.com

 Vaccination significantly reduced the incidence of virologically confirmed dengue and showed acceptable safety and reactogenicity profiles, findings that were consistent with earlier results.



Conclusion Thecasesolutions.com

In conclusion, available data from the efficacy and long-term follow-up surveillance periods across three studies in Asian—Pacific and Latin American tropical and subtropical regions in which dengue is endemic showed a reduction in dengue disease in the efficacy surveillance phase among children who received the vaccine. In addition, there was a lower risk of hospitalization for dengue overall for up to 2 years after completion of the three-dose vaccination schedule among children between the ages of 9 and 16 years

Issue applied in Ecuador

It has not been tested in Ecuador yet

in Ecuador

d in Ecuador ve

tions.con

Conclusion Thecasesolutions.com

In conclusion, available data from the efficacy and long-term follow-up surveillance periods across three studies in Asian–Pacific and Latin American tropical and subtropical regions in which dengue is endemic showed a reduction in dengue disease in the efficacy surveillance phase among children who received the vaccine. In addition, there was a lower risk of hospitalization for dengue overall for up to 2 years after completion of the three-dose vaccination schedule among children between the ages of 9 and 16 years.



